Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

Inclusion Criteria: 1. HIV-1 infected patients. 2. Age\> 18 years. 3. Receiving stable antiretroviral treatment for at least 3 months. 4. Current or historical treatment with 3TC or FTC. 5. Willing to change antiretroviral treatment due to intolerance or interest in simplification. 6. Undetectable viral load (\<50 cop/mL) for at least 1 year prior to the inclusion. A single viral load \>50cop/ml (≤500 copies/ml) is allowed before the three months prior to inclusion in the study, preceded and followed by an undetectable determination. 7. Current level of CD4\> 350 cells/μL. 8. Naïve to integrase inhibitors. 9. Patient able to understand and give written informed consent. 10. For those included in group 1 (20 patients): No previous history of virological failure with ART regimen that included 3TC or FTC or previous virological failure had a population genotype without M184V/I or K65R/E/N mutations. 11. For those included in group 2 (20 patients): previous history of virological failure with ART regimen that included 3TC or FTC and historical genotype with M184V/I or K65R/E/N mutations. Exclusion Criteria: 1. Detection of any of the following mutations in proviral DNA in peripheral blood by conventional sequencing: M184V/I or K65R/E/N. 2. Pregnant, lactating or child-bearing women who do not commit to using an adequate contraceptive method.